<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353648</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103143</org_study_id>
    <nct_id>NCT04353648</nct_id>
  </id_info>
  <brief_title>Assessing Muscle Metabolic Phenotype by MSK Ultrasound</brief_title>
  <official_title>Assessment of Muscle Metabolic Phenotype by the Use of Point-of-care MSK Ultrasound Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether ultrasound images (pictures) can be used as a
      valid assessment of muscle quality in different muscle groups during Intensive Care stay.
      This new approach would allow clinicians to obtain frequent skeletal muscle images and would
      enable doctors to observe any changes over time in muscle quality that could occur during ICU
      stay.

      Participants in this study will have ultrasound images made of their leg-, chest- and jaw
      muscles taken on every day until ICU discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Quality from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>Ultrasound-derived area of intramuscular adipose tissue (IMAT) and intramuscular glycogen content from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle volume and thickness from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>Ultrasound-derived volume and thicknessfrom the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the psoas at the Level of L3/L4</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the intercostal muscle at the Level of Th3/Th4</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the intercostal muscle at the Level of the head</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ultrasound</condition>
  <arm_group>
    <arm_group_label>Duke ICU/Trauma Center Patients</arm_group_label>
    <description>Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to a Duke Trauma center, SICU, MICO, or CT ICU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission Duke Trauma center, SICU, MICU, or CT ICU

          -  &gt;18 years of age

        Exclusion Criteria:

          -  &lt;18 years of age

          -  prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Wischmeyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Molinger</last_name>
    <phone>9196816437</phone>
    <email>jeroen.molinger@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Wischmeyer</last_name>
    <phone>9196816437</phone>
    <email>paul.wischmeyer@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Molinger</last_name>
      <phone>919-681-6437</phone>
      <email>jeroen.molinger@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Wischmeyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

